Skip to main content

Scavidin: a fusion gene for the treatment of cancer

Objetivo

The main objective of the proposal is to develop a new target-specific delivery system for the treatment of malignant glioma. For that purpose we have cloned a new fusion gene "Cave-in" which contains intracellular and membrane-spanning domains of scavenger receptor legated to avid in which will form the extra cellular domain of the fusion protein. Cave-in will be transfixed to target tissue with local gene therapy via catheter delivery or during surgical operation with adenovirus or pseudotyped retrovirus technology. Targeted treatment is achieved by binding of biotinylated compounds to Cave-in, which will be only expressed in the transfixed tissue.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

UNIVERSITY OF KUOPIO
Dirección
Savilahdentie 9
1627 Kuopio
Finlandia

Ver en el mapa

Participantes (3)

ARK THERAPEUTICS LTD.
United Kingdom
Dirección
Warren Mews 6
W1T 6AR London

Ver en el mapa

ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italia
Dirección
Via Filodrammatici 8
20121 Milano

Ver en el mapa

UNIVERSITY COLLEGE LONDON
United Kingdom
Dirección
Mortimer Street The Middlesex Hospital
W1N 8AA London

Ver en el mapa